21 C.F.R. §341.76 - Labeling of bronchodilator drug products

Cite as21 C.F.R. §341.76
    • This document is available in original version only for vLex customers

      View this document and try vLex for 7 days
    • TRY VLEX
1 cases
  • Green v. Bdi Pharmaceuticals, 35,291-CA.
    • United States
    • Court of Appeal of Louisiana (US)
    • 31 Octubre 2001
    ...as reasonably anticipated use. BDI further argued that because its labels comply with Food and Drug Administration regulations, 21 C.F.R. §§ 341.76, 341.78, the sufficiency of the warning is preempted by Federal law, 21 U.S.C. § 379r (a). Finally, BDI argued that not only was Green's defect......

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT